Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 2/20 | 0.50 |
| ▸ | CPB1 | P15086 | 1/20 | 0.50 |
| ▸ | CPA3 | P15088 | 1/20 | 0.50 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 2/20 | 0.47 |
| ▸ | MME | P08473 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2295761 | 1.00 | CPA1 (0.50) | CPA1CPB1CPA3CPB2LTA4H | |
| SCHEMBL16501759 | 0.87 | MEN1 (0.43) | CPA1MMEMEN1KMT2ACYP3A4 | |
| SCHEMBL22872302 | 0.84 | CPA3 (0.53) | CPA3MMEMEN1KMT2ACYP3A4 | |
| SCHEMBL7506620 | 0.81 | CPA1 (0.55) | CPA1CPB1CPA3CPB2LTA4H | |
| SCHEMBL7745276 | 0.81 | MAPK1 (0.53) | MEN1KMT2ACYP3A4MAPK1MAPT | |
| SCHEMBL10245188 | 0.81 | MAPK1 (0.53) | MEN1KMT2ACYP3A4MAPK1MAPT | |
| SCHEMBL4302711 | 0.81 | CPA1 (0.55) | CPA1CPB1CPA3CPB2LTA4H | |
| SCHEMBL8254401 | 0.81 | MAPK1 (0.53) | MEN1KMT2ACYP3A4MAPK1MAPT | |
| SCHEMBL20272616 | 0.81 | CPA1 (0.55) | CPA1CPB1CPA3CPB2LTA4H | |
| SCHEMBL22457979 | 0.80 | MME (0.56) | MMECYP3A4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216420-A1 | HYDROPHOBIC AURISTATIN F COMPOUNDS AND CONJUGATES THEREOF | SEAGEN INC (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240216420-A1 | HYDROPHOBIC AURISTATIN F COMPOUNDS AND CONJUGATES THEREOF | SEAGEN INC (US) | 2024-07-04 | — | — | US | disclosed |
| US-11857565-B2 | Hydrophobic Auristatin F compounds and conjugates thereof | SEAGEN INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11857565-B2 | Hydrophobic Auristatin F compounds and conjugates thereof | SEAGEN INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20210008099-A1 | HYDROPHOBIC AURISTATIN F COMPOUNDS AND CONJUGATES THEREOF | SEATTLE GENETICS, INC. (US) | 2021-01-14 | — | — | US | disclosed |
| EP-2441755-A1 | Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors | Almirall, S.A. (ES) | 2012-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210008099-A1 | HYDROPHOBIC AURISTATIN F COMPOUNDS AND CONJUGATES THEREOF | MSN, AURKA, AURKC | CPA1 3227/4885CPB1 2509/4885CPA3 2340/4885 |
| US-11857565-B2 | Hydrophobic Auristatin F compounds and conjugates thereof | MSN, AURKA, AURKC | CPA1 3227/4885CPB1 2509/4885CPA3 2340/4885 |
| US-20240216420-A1 | HYDROPHOBIC AURISTATIN F COMPOUNDS AND CONJUGATES THEREOF | MSN, AURKA, AURKC | CPA1 3227/4885CPB1 2509/4885CPA3 2340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.